v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 139,915 $ 180,571
Short-term available-for-sale investments 5,397 23,739
Accounts receivable, less allowance for doubtful accounts of $3,293 and $4,738, respectively 227,887 218,468
Inventories 179,496 171,638
Current assets held-for-sale 26,669 0
Other current assets 31,286 27,066
Total current assets 610,650 621,482
Property and equipment, net 243,728 226,200
Right-of-use assets 97,258 98,326
Goodwill 970,966 872,737
Intangible assets, net 526,428 534,645
Other assets 272,140 285,302
Total assets 2,721,170 2,638,692
Current liabilities:    
Trade accounts payable 28,895 25,679
Salaries, wages and related accruals 44,313 36,747
Accrued expenses 17,806 14,880
Contract liabilities 30,108 23,069
Income taxes payable 12,082 12,022
Operating lease liabilities - current 12,978 11,199
Contingent consideration payable 0 3,500
Current liabilities held-for-sale 689 0
Other current liabilities 2,949 1,413
Total current liabilities 149,820 128,509
Deferred income taxes 63,666 88,982
Long-term debt obligations 389,000 350,000
Operating lease liabilities 92,752 93,766
Other long-term liabilities 11,557 10,919
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,554,366 and 157,641,914 respectively 1,576 1,576
Additional paid-in capital 790,418 721,543
Retained earnings 1,297,688 1,309,461
Accumulated other comprehensive loss (75,307) (66,064)
Total Bio-Techne's shareholders' equity 2,014,375 1,966,516
Total liabilities and shareholders' equity $ 2,721,170 $ 2,638,692

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL